In view of the fact that patients with CD8+PD-1+CD161+ T cells enriched next to the cancer have better outcomes and the anti-PD-L1 treatment of mice, and it can be considered as a potential prognostic indicator and may benefit from anti-PD-L1 treatment. The gene discussed is CD8A; the disease is cancer.